[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MY166063A - Intravenous antiviral treatments - Google Patents

Intravenous antiviral treatments

Info

Publication number
MY166063A
MY166063A MYPI20083086A MYPI20083086A MY166063A MY 166063 A MY166063 A MY 166063A MY PI20083086 A MYPI20083086 A MY PI20083086A MY PI20083086 A MYPI20083086 A MY PI20083086A MY 166063 A MY166063 A MY 166063A
Authority
MY
Malaysia
Prior art keywords
antiviral treatments
intravenous
intravenous antiviral
treatments
kits
Prior art date
Application number
MYPI20083086A
Inventor
Yarlagadda Sudhakara Babu
Pooran Chand
Shanta Bantia
Shane Arnold
John Michael Kilpatrick
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY166063(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2006/013535 external-priority patent/WO2007117241A1/en
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MY166063A publication Critical patent/MY166063A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides unit dosage forms, kits, and methods useful for treating viral infections.
MYPI20083086A 2006-02-13 2008-08-13 Intravenous antiviral treatments MY166063A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77274806P 2006-02-13 2006-02-13
PCT/US2006/013535 WO2007117241A1 (en) 2006-04-12 2006-04-12 Intramuscular antiviral treatments
PCT/US2007/003755 WO2007095218A1 (en) 2006-02-13 2007-02-12 Intravenous antiviral treatments

Publications (1)

Publication Number Publication Date
MY166063A true MY166063A (en) 2018-05-23

Family

ID=38169715

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20083086A MY166063A (en) 2006-02-13 2008-08-13 Intravenous antiviral treatments

Country Status (11)

Country Link
EP (1) EP1986626A1 (en)
JP (3) JP2009538822A (en)
KR (9) KR101992585B1 (en)
AU (2) AU2007215156A1 (en)
BR (1) BRPI0707769A2 (en)
CA (1) CA2642260C (en)
EA (1) EA025483B1 (en)
HK (1) HK1212250A1 (en)
MX (2) MX2020002008A (en)
MY (1) MY166063A (en)
WO (1) WO2007095218A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025483B1 (en) * 2006-02-13 2016-12-30 Байокрист Фармасьютикалз, Инк. Intravenous method for treating a seasonal influenza
CN101367750B (en) * 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1S,2S,3S,4R)-3-[(1S)-1-acet-ammonia-2-ethyl-butyl]-4- guanidino-2-hydroxyl-cyclopentyl-1-carboxylic acid aqua compound and medical uses thereof
KR20220033561A (en) 2020-09-07 2022-03-17 주식회사 경보제약 Pharmaceutical composition of premix formulation containing peramivir compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT933993E (en) * 1996-06-14 2006-10-31 Biocryst Pharm Inc SUBSTITUTED CYCLOPENTANEUS COMPOUNDS, UTEIS AS NEURAMINIDASE INHIBITORS
KR20010024743A (en) * 1997-12-17 2001-03-26 몽고메리 죤 에이 Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
GB0015324D0 (en) 2000-06-22 2000-08-16 Biota Scient Management Medicaments
EA025483B1 (en) * 2006-02-13 2016-12-30 Байокрист Фармасьютикалз, Инк. Intravenous method for treating a seasonal influenza

Also Published As

Publication number Publication date
CA2642260A1 (en) 2007-08-23
KR20080096829A (en) 2008-11-03
BRPI0707769A2 (en) 2011-05-10
KR20180024027A (en) 2018-03-07
KR102194015B1 (en) 2020-12-22
JP2013256527A (en) 2013-12-26
JP2009538822A (en) 2009-11-12
KR20210076189A (en) 2021-06-23
AU2007215156A1 (en) 2007-08-23
KR102475176B1 (en) 2022-12-07
KR101992585B1 (en) 2019-06-25
KR20190072681A (en) 2019-06-25
KR102267754B1 (en) 2021-06-23
EP1986626A1 (en) 2008-11-05
KR101992585B9 (en) 2022-09-20
EA025483B1 (en) 2016-12-30
AU2013216632A1 (en) 2013-08-29
AU2013216632B2 (en) 2016-09-01
HK1212250A1 (en) 2016-06-10
KR20230003248A (en) 2023-01-05
EA200870263A1 (en) 2009-06-30
CA2642260C (en) 2016-08-09
MX2008010394A (en) 2009-01-12
KR20140132778A (en) 2014-11-18
KR20200143519A (en) 2020-12-23
KR20210135632A (en) 2021-11-15
KR102323339B1 (en) 2021-11-08
KR20160129105A (en) 2016-11-08
JP6073202B2 (en) 2017-02-01
WO2007095218A1 (en) 2007-08-23
JP2015180695A (en) 2015-10-15
MX2020002008A (en) 2020-07-13

Similar Documents

Publication Publication Date Title
MX2010002318A (en) 2,3-substituted azaindole derivatives for treating viral infections.
CY1122522T1 (en) META ARSENICODE SODIUM FOR USE IN THE MANAGEMENT OF MULTIPLE MYELOMA
MX2009006536A (en) Organic compounds and their uses.
MX2009009761A (en) Compositions and kits for treating influenza.
WO2009105513A8 (en) Novel compounds and methods for therapy
WO2008127364A3 (en) Antiviral compounds and use thereof
MX2009008617A (en) Use of il-23 antagonists for treatment of infection.
MX360301B (en) Boron-containing small molecules as anti-inflammatory agents.
UA118645C2 (en) METHOD OF COMBINED CANCER THERAPY OF NANOPARTICLES CONTAINING RAPAMYCINE AND ALBUMIN
WO2009149179A3 (en) Enhanced antiviral therapy methods and devices
MX2009008222A (en) Activin-actriia antagonists and uses for treating or preventing breast cancer.
MX348481B (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases.
WO2008115281A3 (en) Compounds for treating viral infections
TNSN08400A1 (en) Organic compounds and their uses
EA200971068A1 (en) TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS
MX2010006206A (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases.
MX2008015775A (en) Compounds and compositions for treatment of cancer.
MXPA04006572A (en) Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections.
TN2011000204A1 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
TNSN08496A1 (en) Aminothiazoles and their uses
MX2009012767A (en) Methods of treating fungal infections.
MX2009009693A (en) Methods of activating irs-1 and akt.
WO2007132355A3 (en) Compositions and methods for inhibiting viral adhesion
MY166063A (en) Intravenous antiviral treatments
EA200971067A1 (en) TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS